Leslie A. Sandusky‐Beltran

This study shows that targeting truncated tau protein with a monoclonal antibody reduces tau levels, improves neuronal function, and decreases microglia activation in tauopathy mouse models.

This study identifies GPRC6A as a key regulator of mTORC1 signaling and tau pathology in tauopathies, showing that targeting GPRC6A could reduce tau accumulation and related neurodegeneration.